JCU > Research Portfolio > Mrs Jenna Pinchbeck

About

Teaching

SP4103: Clinical Exercise Physiology 1 (Level 4; TSV)

Research Disciplines

Socio-Economic Objectives

Publications

These are the most recent publications associated with this author. To see a detailed profile of all publications stored at JCU, visit ResearchOnline@JCU. Hover over Altmetrics badges to see social impact.

Journal Articles

Golledge J, Yip L, Fernando M, Pinchbeck J, Rowbotham S, Jenkins J and Leicht A (2021) Relationship between requirement to stop during a six-minute walk test and health-related quality of life, physical activity and physical performance amongst people with intermittent claudication. Annals of Vascular Surgery, 76. pp. 363-369
Matthews E, Pinchbeck J, Elmore K, Jones R, Moxon J and Golledge J (2021) The reproducibility of measuring maximum abdominal aortic aneurysm diameter from ultrasound images. The Ultrasound Journal, 13.
Golledge J, Moxon J, Rowbotham S, Pinchbeck J, Quigley F and Jenkins J (2020) High ankle brachial index predicts high risk of cardiovascular events amongst people with peripheral artery disease. PLoS ONE, 15 (11).
Golledge J, Pinchbeck J, Tomee S, Rowbotham S, Singh T, Moxon J, Jenkins J, Lindeman J, Dalman R, McDonnell L, Fitridge R, Morris D and TEDY Investigators (2020) Efficacy of Telmisartan to slow growth of small abdominal aortic aneurysms: a randomized clinical trial. Jama Cardiology, 5 (12). pp. 1374-1381
Golledge J, Pinchbeck J, Rowbotham S, Yip L, Jenkins J, Quigley F and Moxon J (2020) Health-related quality of life amongst people diagnosed with abdominal aortic aneurysm and peripheral artery disease and the effect of fenofibrate. Scientific Reports, 10.
Golledge J, Leicht A, Yip L, Rowbotham S, Pinchbeck J, Jenkins J, Clapperton R, Dally-Watkins M, Fiatarone Singh M, Mavros Y, Noble Y, Haghighi M, Hollings M, Parmenter B and Burton N (2020) Relationship between disease specific quality of life measures, physical performance, and activity in people with intermittent claudication caused by peripheral artery disease. European Journal of Vascular and Endovascular Surgery, 59 (6). pp. 957-964
Moxon J, Rowbotham S, Pinchbeck J, Lazzaroni S, Morton S, Moran C, Quigley F, Jenkins J, Reid C, Cavaye D, Jaeggi R and Golledge J (2020) A randomised controlled trial assessing the effects of peri-operative fenofibrate administration on abdominal aortic aneurysm pathology: outcomes from the FAME trial. European Journal of Vascular and Endovascular Surgery, 60 (3). pp. 452-460
Golledge J, Singh T, Alahakoon C, Pinchbeck J, Yip L, Moxon J and Morris D (2019) Meta-analysis of clinical trials examining the benefit of structured home exercise programmes in patients with peripheral artery disease. British Journal of Surgery, 106. pp. 319-331
Golledge J, Morris D, Pinchbeck J, Rowbotham S, Jenkins J, Bourke M, Bourke B, Norman P, Jones R and Moxon J (2019) Metformin prescription is associated with reduced risk of surgical repair and rupture-related mortality in patients with abdominal aortic aneurysm. European Journal of Vascular and Endovascular Surgery, 57 (1). pp. 94-101
Golledge J, Moxon J, Rowbotham S, Pinchbeck J, Yip L, Velu R, Quigley F, Jenkins J and Morris D (2018) Risk of major amputation in patients with intermittent claudication undergoing early revascularization. British Journal of Surgery, 105 (6). pp. 699-708
Pinchbeck J, Moxon J, Rowbotham S, Bourke M, Lazzaroni S, Morton S, Matthews E, Hendy K, Jones R, Bourke B, Jaeggi R, Favot D, Quigley F, Jenkins J, Reid C, Velu R and Golledge J (2018) A randomized placebo-controlled trial assessing the effect of 24 weeks fenofibrate therapy on circulating markers of abdominal aortic aneurysm: outcomes from the FAME-2 trial. Journal of the American Heart Association, 7 (19).

Current Funding

Current and recent Research Funding to JCU is shown by funding source and project.

Commonwealth Department of Health - Medical Research Future Fund - Cardiovascular Health Mission

Improving clinical pathways for abdominal aortic aneurysm through incorporating biomarkers

Indicative Funding: $1,000,000 over 3 years
Summary: 20 million people worldwide have weakening of their main abdominal artery (abdominal aortic aneurysm; AAA) and are at high risk of both major adverse cardiovascular events (MACE) and AAA related events (AAA repair and rupture-related death). Most AAAs are identified at a small size when their risk of rupture is low. Management of small AAA focuses on repeat aortic imaging every 6 months to identify when the threshold diameter (50mm in women and 55mm in men) is reached for elective surgical AAA repair. Most small AAAs continue to grow in size and eventually undergo repair. No drugs have been shown to limit AAA growth and the clinical pathway focuses on identifying those needing surgery rather than medical management. There are no established means to individualise care. Our interviews with patients and health professionals indicate that the number one deficiency in current AAA management is the lack of individualising medical management to reduce the high incidence of MACE and AAA related events. Our international AAA alliance is uniquely placed due to our resources (biobank-registry) and IP (bioinformatics, clinical, engineering software, genomics, biomarkers, machine learning and pathogenesis) to addresses this unmet clinical need.
Investigators: Jon Golledge, Clare Arnott, Thomas Gasser, Rebecca Evans, Joseph Moxon, Matt Field, Jenna Pinchbeck, Aaron Drovandi, Dylan Morris, Svetha Venkatesh, Truyen Tran, Catherine Rush, Aletta Schutte, Robyn Clay-Williams and Geoffrey Jones (College of Medicine & Dentistry, The George Institute for Global Health, KTH Royal Institute of Technology, College of Public Health, Medical & Vet Sciences, Townsville Hospital and Health Services, Deakin University, The University of New South Wales, Macquarie University and University of Otago)
Keywords: Prevention; Complications; Peripheral artery disease; Risk Factors

Commonwealth Department of Health - Medical Research Future Fund - Dementia, Ageing and Aged Care

METformin for treating peripheral artery disease Related walking Impairment Trial (MERIT)

Indicative Funding: $1,215,182 over 3 years
Summary: Peripheral artery disease (PAD) is a very common chronic cardiovascular disease of ageing affecting approximately 1 million older Australians and causing substantial leg pain on walking (intermittent claudication), marked functional impairment, reduced quality of life (QOL) and very high risk of major adverse cardiovascular and limb events. Vulnerable populations (e.g. regional or remote, lower income and Aboriginal and Torres Strait Islander populations) have much greater PAD-related burden. Our past consultations with patients indicate that improvements in walking is their number one priority. The only widely available PAD treatment in Australia is revascularisation but this does not improve walking distance and has substantial safety concerns. Multiple lines of evidence suggest that metformin safely improves leg blood supply. MERIT is a placebo-controlled randomised trial performed across 7 sites. The importance of the trial has been endorsed by patients, Heart Foundation, Queensland Health and Australian and New Zealand Society for Vascular Surgery and Alliance for Cardiovascular Trials. If positive, MERIT will identify a cheap, safe and widely available drug to improve the function and QOL of millions of older adults worldwide who have PAD.
Investigators: Jon Golledge, Clare Arnott, Edward Strivens, Belinda Parmenter, Clare Heal, Christopher Reid, Aaron Drovandi, Joseph Moxon, Jenna Pinchbeck, Richard Norman, Dylan Morris, Christopher Askew, Sarah Larkins, Rachel Quigley and Yvonne Cadet-James (College of Medicine & Dentistry, The George Institute for Global Health, The University of New South Wales, Curtin University of Technology, Townsville Hospital and Health Services, University of the Sunshine Coast and Indigenous Education & Research Centre)
Keywords: Prevention; Complications; Peripheral artery disease; Risk Factors

Collaboration

The map shows research collaborations by institution from the past 7 years.
Note: Map points are indicative of the countries or states that institutions are associated with.